|
As part of our COBRE lecture series, on May 11th, 2021 the COBRE welcomed Dr. R. Kathryn McHugh, a clinical researcher and practitioner whose research focuses on the nature and treatment of anxiety and substance use disorder. In her talk, Dr. McHugh discussed the association between mental health and opioid misuse across the spectrum of severity, focusing on the overlap between suicide and unintentional overdose and the role of benzodiazepines in opioid use disorder.
Dr. McHugh is an Associate Psychologist in the Division of Alcohol, Drugs, and Addiction at McLean Hospital and an Associate Professor in the Department of Psychiatry at Harvard Medical School. She has received numerous awards, published more than 140 manuscripts and book chapters, and edited a book on the dissemination of evidence-based treatments.
|
|
|
|
Watch Dr. McHugh's presentation here.
|
|
|
Implementation support for contingency management: preferences of opioid treatment program leaders and staff. Scott K, Jarman S, Moul S, Murphy CM, Yap K, Garner BR, Becker SJ. Implement Sci Commun. 2021 Apr 30;2(1):47. doi: 10.1186/s43058-021-00149-2. PMID: 33931126
|
|
|
Moderating effects of sleep difficulties on relations between posttraumatic stress disorder symptoms and positive memory count. Contractor AA, Slavish DC, Weiss NH, Alghraibeh AM, Alafnan AA, Taylor DJ. J Clin Psychol. 2021 Apr 19. doi: 10.1002/jclp.23142. Online ahead of print. PMID: 33871878
|
|
|
Critical considerations for the positive memory-posttraumatic stress disorder model. Contractor AA, Banducci AN, Weiss NH. Clin Psychol Psychother. 2021 Apr 18. doi: 10.1002/cpp.2599. Online ahead of print. PMID: 33870586 Review.
|
|
|
What parents of adolescents in residential substance use treatment want from continuing care: A content analysis of online forum posts. Helseth SA, Scott K, Escobar KI, Jimenez F, Becker SJ. Subst Abus. 2021 May 4:1-10. doi: 10.1080/08897077.2021.1915916. Online ahead of print. PMID: 33945453
|
|
Characteristics of post-overdose public health-public safety outreach in Massachusetts.
Formica SW, Waye KM, Benintendi AO, Yan S, Bagley SM, Beletsky L, Carroll JJ, Xuan Z, Rosenbloom D, Apsler R, Green TC, Hunter A, Walley AY. Drug Alcohol Depend. 2021 Feb 1;219:108499. doi: 10.1016/j.drugalcdep.2020.108499. Epub 2020 Dec 31. PMID: 33421800
|
|
|
For a list of upcoming COBRE, National and local events and webinars, visit the COBRE's Event page.
|
|
|
NOT-AA-21-028
Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes
Release Date: May 5, 2021
Due Date: June 5, 2021
Expiration Date: September 8, 2024
This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.
|
|
|
For a list of federal and government related opioid and substance misuse related funding opportunities, visit here.
|
|
Research Biologist Position
Ocean State Research Institute at the Providence
VA Medical Center
The Providence VA Medical Center is one of the affiliated teaching institutions of The Warren Alpert Medical School of Brown University. The successful candidate must qualify for a full-time medical faculty position at the rank of Assistant or Associate Professor in the Department of Medicine at The Warren Alpert Medical School of Brown University. Minimum requirements include: PhD or MD/PhD or MD in a discipline relevant to lung or cardiovascular pathobiology plus at least two years of post-doctoral research training and a commitment to scholarly participation in the research programs of the CardioPulmonary Vascular Biology Center for BioMedical Research Excellence (CPVB COBRE) based at Ocean State Research Institute at the Providence VA Medical Center. Experience in research on the pulmonary circulation and/or mitochondrial biology are highly desirable. Candidates for an Associate Professor position must have independent research support and a national reputation for research accomplishment.
For More Information
Apply Here
|
|
Episode 1: An Epidemic Within a Pandemic
"In this episode, Ruth Katz hosts addiction medicine specialist Dr. Kelly Clark and community paramedic Daniel Sledge to understand how the COVID-19 pandemic has impacted the response to the opioid epidemic and treatment for individuals with substance use disorders in the United States. They discuss the barriers and opportunities at the individual, first-responder, clinician, and systems level while offering insight into changes in the national response, resources, and tools since the onset of the pandemic. Kelly and Daniel also share their experiences working to support those with opioid use disorder and offer advice on the tools, policies, and multi-sector collaboration needed to combat the U.S. opioid crisis. Listen for more on how treatment providers evaluate the response to the opioid epidemic within the COVID-19 pandemic."
|
|
FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose
"The U.S. Food and Drug Administration announced today the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products."
|
|
|
|
